Xiong Jicheng, Liang Shuoming, Lu Simiao, Chen Hainan, Wang Ziwei, Meng Hao, Zhu Yi, Han Yongtao, Leng Xuefeng
School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
School of Clinical Medicine, Chengdu Medical College, Chengdu, China.
Front Oncol. 2025 Sep 10;15:1629335. doi: 10.3389/fonc.2025.1629335. eCollection 2025.
This study aims to update the prognostic value of perineural invasion(PNI) in various subgroups of esophageal cancer patients.
We searched databases including PubMed, Scopus, Wiley, Web of Science, and Embase for full-text articles published in English on esophageal cancer related to PNI. The search was conducted up to January 1, 2024. We summarized the hazard ratios (HR) and 95% confidence intervals (CI) for overall survival (OS), disease-free survival (DFS), as well as recurrence and metastasis, to assess the prognostic value of PNI in patients with esophageal cancer.
A total of 38 eligible studies were ultimately included. Thirty-two studies, encompassing a total of 7157 patients, reported the correlation between PNI and OS. The results indicated that PNI is significantly associated with poor OS in esophageal cancer patients (HR = 1.54, 95% CI: 1.41-1.68, P < 0.00001). Eleven studies, including a total of 2224 patients, reported the correlation between PNI and DFS. These studies found that PNI is significantly associated with poor DFS (HR = 1.43, 95% CI: 1.25-1.62, P < 0.00001). Three studies, including a total of 1125 patients, reported no correlation between PNI and recurrence (HR = 1.17, 95% CI: 0.62-2.18, P = 0.63). Two studies, including a total of 556 patients, reported a correlation between PNI and distant metastasis (HR = 2.19, 95% CI: 1.02-4.73, P = 0.04). Further subgroup analysis revealed that PNI is an independent prognostic factor for esophageal squamous cell carcinoma (ESCC) (OS: HR=1.62, 95%CI: 1.35-1.94, P<0.00001; DFS: HR=1.28, 95%CI: 1.03-1.59, P=0.03); however, in esophageal adenocarcinoma, PNI is not associated with OS or DFS (OS: HR=1.23, 95%CI: 1.00-1.53, P=0.05; DFS: HR=1.65, 95%CI: 0.95-2.87, P=0.08). PNI positivity is associated with unfavorable outcomes, irrespective of neoadjuvant therapy receipt. In the non-Asian subgroup, PNI is not statistically significant for poor DFS prognosis.
PNI is a histological marker of aggressive disease and can serve as an independent prognostic factor for patients with esophageal cancer. PNI positivity can predict poor outcomes in ESCC, but its role as a prognostic indicator for adenocarcinoma requires further investigation.
本研究旨在更新神经周围浸润(PNI)在食管癌患者各亚组中的预后价值。
我们检索了包括PubMed、Scopus、Wiley、Web of Science和Embase在内的数据库,以查找发表的与PNI相关的英文食管癌全文文章。检索截至2024年1月1日。我们汇总了总生存(OS)、无病生存(DFS)以及复发和转移的风险比(HR)和95%置信区间(CI),以评估PNI在食管癌患者中的预后价值。
最终共纳入38项符合条件的研究。32项研究,共纳入7157例患者,报告了PNI与OS之间的相关性。结果表明,PNI与食管癌患者OS较差显著相关(HR = 1.54,95% CI:1.41 - 1.68,P < 0.00001)。11项研究,共纳入2224例患者,报告了PNI与DFS之间的相关性。这些研究发现,PNI与DFS较差显著相关(HR = 1.43,95% CI:1.25 - 1.62,P < 0.00001)。3项研究,共纳入1125例患者,报告PNI与复发之间无相关性(HR = 1.17,95% CI:0.62 - 2.18,P = 0.63)。2项研究,共纳入556例患者,报告PNI与远处转移之间存在相关性(HR = 2.19,95% CI:1.02 - 4.73,P = 0.04)。进一步的亚组分析显示,PNI是食管鳞状细胞癌(ESCC)的独立预后因素(OS:HR = 1.62,95% CI:1.35 - 1.94,P < 0.00001;DFS:HR = 1.28,95% CI:1.03 - 1.59,P = 0.03);然而,在食管腺癌中,PNI与OS或DFS无关(OS:HR = 1.23,95% CI:1.00 - 1.53,P = 0.05;DFS:HR = 1.65,95% CI:0.95 - 2.87,P = 0.08)。无论是否接受新辅助治疗,PNI阳性都与不良结局相关。在非亚洲亚组中,PNI对DFS预后不良无统计学意义。
PNI是侵袭性疾病的组织学标志物,可作为食管癌患者的独立预后因素。PNI阳性可预测ESCC的不良结局,但其作为腺癌预后指标的作用需要进一步研究。